Literature DB >> 21798112

Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.

C J A Morgan1, C Gardener1, G Schafer1, S Swan1, C Demarchi1, T P Freeman1, P Warrington1, I Rupasinghe1, A Ramoutar1, N Tan1, G Wingham1, S Lewis1, H V Curran1.   

Abstract

BACKGROUND: Cannabis varies considerably in levels of its two major constituent cannabinoids - (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Recently, we found evidence that those who smoked cannabis containing detectable levels of CBD had fewer psychotic-like symptoms than those whose cannabis had no CBD. The present study aimed, first, to replicate those findings and, second, to determine whether protective effects of CBD may extend to other harms of cannabis, such as memory impairment and reduced psychological well-being.
METHOD: A total of 120 current cannabis smokers, 66 daily users and 54 recreational users were classified into groups according to whether analysis of their hair revealed the presence or absence of CBD and high versus low levels of THC. All were assessed on measures of psychosis-like symptoms, memory (prose recall; source memory) and depression/anxiety.
RESULTS: Lower psychosis-like symptoms were found in those whose hair had CBD compared with those without. However, this was seen only in recreational users, who had higher levels of THC in their hair. Higher THC levels in hair were associated with increased depression and anxiety. Prose recall and source memory were poorer in daily users with high THC levels in hair while recognition memory was better in individuals with CBD present in hair.
CONCLUSIONS: CBD attenuates the psychotic-like effects of cannabis over time in recreational users. Higher THC negatively impacts on memory and psychological well-being. These findings raise concerns for the harms stemming from use of varieties such as 'skunk' (sensimillia), which lack any CBD but currently dominate the supply of cannabis in many countries.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21798112     DOI: 10.1017/S0033291711001322

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  65 in total

Review 1.  Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Authors:  Marc W Manseau; Donald C Goff
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

2.  Towards a better cannabis drug.

Authors:  Raphael Mechoulam; Linda Parker
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

3.  Cannabis, a complex plant: different compounds and different effects on individuals.

Authors:  Zerrin Atakan
Journal:  Ther Adv Psychopharmacol       Date:  2012-12

Review 4.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

Review 5.  Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives.

Authors:  Alison C Burggren; Anaheed Shirazi; Nathaniel Ginder; Edythe D London
Journal:  Am J Drug Alcohol Abuse       Date:  2019-07-31       Impact factor: 3.829

Review 6.  Interactions between recreational cannabis use and cognitive function: lessons from functional magnetic resonance imaging.

Authors:  Kelly A Sagar; Staci A Gruber
Journal:  Ann N Y Acad Sci       Date:  2018-11-13       Impact factor: 5.691

Review 7.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

Review 8.  Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies.

Authors:  Ziva D Cooper; Donald I Abrams
Journal:  Am J Drug Alcohol Abuse       Date:  2019-11-05       Impact factor: 3.829

9.  Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley rats.

Authors:  Michael A Taffe; Kevin M Creehan; Sophia A Vandewater
Journal:  Br J Pharmacol       Date:  2015-01-23       Impact factor: 8.739

Review 10.  Affect and cannabis use in daily life: a review and recommendations for future research.

Authors:  Andrea M Wycoff; Jane Metrik; Timothy J Trull
Journal:  Drug Alcohol Depend       Date:  2018-08-15       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.